CN107922425B - 制备parp抑制剂、结晶形式的方法及其用途 - Google Patents

制备parp抑制剂、结晶形式的方法及其用途 Download PDF

Info

Publication number
CN107922425B
CN107922425B CN201680048637.5A CN201680048637A CN107922425B CN 107922425 B CN107922425 B CN 107922425B CN 201680048637 A CN201680048637 A CN 201680048637A CN 107922425 B CN107922425 B CN 107922425B
Authority
CN
China
Prior art keywords
compound
crystalline form
cancer
degrees
def
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680048637.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922425A (zh
Inventor
王鹤翔
周昌友
任博
匡先照
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiji Shenzhou Suzhou Biotechnology Co ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58099633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107922425(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beigene Ltd filed Critical Beigene Ltd
Priority to CN202011223061.6A priority Critical patent/CN112521390A/zh
Publication of CN107922425A publication Critical patent/CN107922425A/zh
Application granted granted Critical
Publication of CN107922425B publication Critical patent/CN107922425B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CN201680048637.5A 2015-08-25 2016-08-22 制备parp抑制剂、结晶形式的方法及其用途 Active CN107922425B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011223061.6A CN112521390A (zh) 2015-08-25 2016-08-22 制备parp抑制剂、结晶形式的方法及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015088003 2015-08-25
CNPCT/CN2015/088003 2015-08-25
PCT/CN2016/096200 WO2017032289A1 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202011223061.6A Division CN112521390A (zh) 2015-08-25 2016-08-22 制备parp抑制剂、结晶形式的方法及其用途

Publications (2)

Publication Number Publication Date
CN107922425A CN107922425A (zh) 2018-04-17
CN107922425B true CN107922425B (zh) 2021-06-01

Family

ID=58099633

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680048637.5A Active CN107922425B (zh) 2015-08-25 2016-08-22 制备parp抑制剂、结晶形式的方法及其用途
CN202011223061.6A Pending CN112521390A (zh) 2015-08-25 2016-08-22 制备parp抑制剂、结晶形式的方法及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202011223061.6A Pending CN112521390A (zh) 2015-08-25 2016-08-22 制备parp抑制剂、结晶形式的方法及其用途

Country Status (15)

Country Link
US (1) US10457680B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341375B1 (cg-RX-API-DMAC7.html)
JP (1) JP6940039B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180041748A (cg-RX-API-DMAC7.html)
CN (2) CN107922425B (cg-RX-API-DMAC7.html)
AU (1) AU2016312011B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003634B1 (cg-RX-API-DMAC7.html)
CA (1) CA2994895A1 (cg-RX-API-DMAC7.html)
EA (1) EA037366B1 (cg-RX-API-DMAC7.html)
IL (2) IL257442B2 (cg-RX-API-DMAC7.html)
MX (1) MX385450B (cg-RX-API-DMAC7.html)
NZ (1) NZ739876A (cg-RX-API-DMAC7.html)
TW (1) TWI736550B (cg-RX-API-DMAC7.html)
WO (1) WO2017032289A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800765B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2797921T3 (cg-RX-API-DMAC7.html) 2011-12-31 2018-02-03
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
WO2018165615A1 (en) 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
EP3654985A4 (en) * 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCERS USING A COMBINATION INCLUDING PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY
CA3097312A1 (en) * 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
TW202002985A (zh) * 2018-06-01 2020-01-16 英屬開曼群島商百濟神州有限公司 在胃癌治療中的parp抑制劑維持療法
USD926356S1 (en) * 2019-03-14 2021-07-27 Tuanfang Liu Battery for electronic cigarette
CN113004279B (zh) * 2019-05-10 2023-01-06 百济神州(苏州)生物科技有限公司 一种控制含parp抑制剂倍半水合物产物的含水量的方法
CN111171001B (zh) * 2019-05-16 2022-04-29 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的结晶方法
CN111171002B (zh) * 2019-05-16 2021-04-06 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的制备方法
MX2021014339A (es) * 2019-05-31 2022-01-06 Beigene Ltd Preparacion de granulo inhibidor de parp y proceso de preparacion del mismo.
CN112007011B (zh) * 2019-05-31 2024-07-23 百济神州(苏州)生物科技有限公司 一种parp抑制剂微丸胶囊及其制备工艺
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2004063198A1 (en) * 2003-01-09 2004-07-29 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
CN103703004A (zh) * 2011-12-31 2014-04-02 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20691B (sl) 1999-01-11 2008-10-31 Agouron Pharma Triciklični inhibitorji poli(ADP-riboza) polimeraz
LT2767537T (lt) 2008-08-06 2017-08-10 Medivation Technologies, Inc. Poli(adp-ribozės)polimerazės (parp) dihidropiridoftalazinono inhibitoriai
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
US11202782B2 (en) * 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
EP3654985A4 (en) * 2017-07-17 2021-04-07 BeiGene, Ltd. TREATMENT OF CANCERS USING A COMBINATION INCLUDING PARP INHIBITORS, TEMOZOLOMIDE AND / OR RADIATION THERAPY
CN113004279B (zh) * 2019-05-10 2023-01-06 百济神州(苏州)生物科技有限公司 一种控制含parp抑制剂倍半水合物产物的含水量的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2004063198A1 (en) * 2003-01-09 2004-07-29 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
CN103703004A (zh) * 2011-12-31 2014-04-02 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Crystalline Polymorphism of Organic Compounds;Mino R. Caira;《Topics in current chemistry》;19980101;第198卷;全文 *
First-principles and direct design approaches for the control of pharmaceutical crystallization;Mitsuko Fujiwara等;《Journal of Process Control》;20050801;第15卷(第5期);全文 *
From Form to Function: Crystallization of Active Pharmaceutical Ingredients;Narayan Variankaval等;《AIChE》;20080603;第54卷(第7期);晶型章节 *
High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids;Sherry L. Morissette等;《Advanced Drug Delivery Reviews》;20040223;第54卷(第7期);全文 *

Also Published As

Publication number Publication date
WO2017032289A1 (en) 2017-03-02
JP6940039B2 (ja) 2021-09-22
IL257442A (en) 2018-04-30
EP3341375B1 (en) 2022-04-13
BR112018003634B1 (pt) 2023-11-21
CA2994895A1 (en) 2017-03-02
IL257442B2 (en) 2023-03-01
CN107922425A (zh) 2018-04-17
US20190177325A1 (en) 2019-06-13
KR20180041748A (ko) 2018-04-24
TW201718586A (zh) 2017-06-01
BR112018003634A8 (pt) 2023-01-17
AU2016312011A1 (en) 2018-03-08
US10457680B2 (en) 2019-10-29
MX2018002322A (es) 2018-04-11
CN112521390A (zh) 2021-03-19
MX385450B (es) 2025-03-18
ZA201800765B (en) 2019-10-30
BR112018003634A2 (en) 2018-11-21
JP2018528199A (ja) 2018-09-27
EA037366B1 (ru) 2021-03-18
AU2016312011B2 (en) 2021-02-04
EP3341375A4 (en) 2019-01-16
EP3341375A1 (en) 2018-07-04
IL296835A (en) 2022-11-01
IL257442B (en) 2022-11-01
EA201890547A1 (ru) 2018-07-31
NZ739876A (en) 2022-09-30
TWI736550B (zh) 2021-08-21

Similar Documents

Publication Publication Date Title
CN107922425B (zh) 制备parp抑制剂、结晶形式的方法及其用途
EP2850082B1 (en) 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
WO2021129820A1 (zh) 含螺环的喹唑啉化合物
WO2022017533A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
CN115433187A (zh) 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
CN107879975A (zh) 组蛋白去乙酰化酶抑制剂及其应用
HK40040143A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof
CN103373971A (zh) 作为蛋白激酶抑制剂的脲类化合物
TW202519531A (zh) 含丙烯酮類生物抑制劑的晶型及其製備方法和應用
HK40061853B (zh) 用作cdk7激酶抑制剂的化合物及其应用
WO2025231053A1 (en) Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
WO2024008083A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
WO2021092892A1 (zh) 喹啉或喹唑啉类化合物在制备抗肿瘤药物中的应用
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210604

Address after: Nine Biological Industrial Parks 218 Sangtian Street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee after: Baiji Shenzhou (Suzhou) Biotechnology Co.,Ltd.

Address before: Greater Cayman, Cayman Islands

Patentee before: BEIGENE, Ltd.